Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janet L Anderl

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Journal of Visualized Experiments : Jove|May 7, 2009
A neuronal and astrocyte co-culture assay for high content analysis of neurotoxicityJanet L Anderl, Stella Redpath, Andrew J Ball
Journal of Experimental & Clinical Cancer Research : CR|January 24, 2015
Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer modelsAmanda F Baker, Neale T Hanke, Barbara J Sands, et al.
European Journal of Immunology|March 8, 2024
Katharina Inholz, Janet L Anderl, Moritz Klawitter, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 8, 2021
Role of Epoxide Hydrolases and Cytochrome P450s on Metabolism of KZR-616, a First-in-Class Selective Inhibitor of the ImmunoproteasomeYing Fang, Henry Johnson, Janet L Anderl, et al.
Journal of Medicinal Chemistry|November 2, 2018
Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2 S,3 R)- N-(( S)-3-(Cyclopent-1-en-1-yl)-1-(( R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-(( S)-2-(2-morpholinoacetamido)propanamido)propenamide)Henry W B Johnson, Eric Lowe, Janet L Anderl, et al.
Biochemical Pharmacology|February 21, 2014
Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924Denise Niewerth, Johan van Meerloo, Gerrit Jansen, et al.
Frontiers in Immunology|March 27, 2023
Zetomipzomib (KZR-616) attenuates lupus in mice via modulation of innate and adaptive immune responsesTony Muchamuel, R Andrea Fan, Janet L Anderl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2011
Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse eventsShirin Arastu-Kapur, Janet L Anderl, Marianne Kraus, et al.
Molecular Pharmacology|April 17, 2014
Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib)Denise Niewerth, Gerrit Jansen, Lesley F V Riethoff, et al.
Elife|November 29, 2017
Immunoproteasome functions explained by divergence in cleavage specificity and regulationMichael B Winter, Florencia La Greca, Shirin Arastu-Kapur, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Journal of Visualized Experiments : Jove|May 7, 2009
A neuronal and astrocyte co-culture assay for high content analysis of neurotoxicityJanet L Anderl, Stella Redpath, Andrew J Ball
Journal of Experimental & Clinical Cancer Research : CR|January 24, 2015
Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer modelsAmanda F Baker, Neale T Hanke, Barbara J Sands, et al.
European Journal of Immunology|March 8, 2024
Katharina Inholz, Janet L Anderl, Moritz Klawitter, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 8, 2021
Role of Epoxide Hydrolases and Cytochrome P450s on Metabolism of KZR-616, a First-in-Class Selective Inhibitor of the ImmunoproteasomeYing Fang, Henry Johnson, Janet L Anderl, et al.
Journal of Medicinal Chemistry|November 2, 2018
Required Immunoproteasome Subunit Inhibition Profile for Anti-Inflammatory Efficacy and Clinical Candidate KZR-616 ((2 S,3 R)- N-(( S)-3-(Cyclopent-1-en-1-yl)-1-(( R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-(( S)-2-(2-morpholinoacetamido)propanamido)propenamide)Henry W B Johnson, Eric Lowe, Janet L Anderl, et al.
Biochemical Pharmacology|February 21, 2014
Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924Denise Niewerth, Johan van Meerloo, Gerrit Jansen, et al.
Frontiers in Immunology|March 27, 2023
Zetomipzomib (KZR-616) attenuates lupus in mice via modulation of innate and adaptive immune responsesTony Muchamuel, R Andrea Fan, Janet L Anderl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2011
Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse eventsShirin Arastu-Kapur, Janet L Anderl, Marianne Kraus, et al.
Molecular Pharmacology|April 17, 2014
Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib)Denise Niewerth, Gerrit Jansen, Lesley F V Riethoff, et al.
Elife|November 29, 2017
Immunoproteasome functions explained by divergence in cleavage specificity and regulationMichael B Winter, Florencia La Greca, Shirin Arastu-Kapur, et al.
Pageof 2